About Bonalive

As the world seeks answers to the growing threat of antibiotic resistance, Smart Healing™ solutions represent a new standard in patient care. Evolving at the intersection of technology and human biology, our technologies reduce antibiotic treatments and enable a better quality of life for patients.

With over 20 years clinical history, and one of the most evidence-based technologies in the industry, we are re-imagining a smarter future for healthcare.

It's time to heal smarter.

bonalive

Diabetic foot osteomyelitis

bonalive

Bonalive Biomaterials Ltd
Biolinja 12, 20750 Turku, Finland
+358 40 177 44 00
contact@bonalive.com
www.bonalive.com

Smart Healing™

9-100003

Bonalive® granules for bone infections

Bonalive® granules is a CE-marked unique bone regeneration technology that naturally inhibits bacterial growth and stimulates bone formation.

Bonalive® granules is effective against 50 clinically relevant bacteria strains, providing surgeons with a 1-stage surgical solution for bone infection treatment.

Based on S53P4 bioactive glass, Bonalive® granules consist solely of elements naturally found in the human body. The granules naturally inhibit bacterial growth in both gram positive and gram negative bacteria, as well as Methicillin resistant bacteria, e.g. MRSA or MRSE.

Indications

- Bone cavity filling
- Bone cavity filling in the treatment of chronic osteomyelitis

Composition

- 53% SiO_2, 23% Na_2O, 20% CaO, 4% P_2O_5

DFO patient

Patient history

50-year-old male with type 1 diabetes and terminal chronic renal failure on hemodialysis. Transmetatarsal amputation of the forefoot. Patient came for observation with a deep plantar-lateral ulcer up to the bone level (cuboid bone) and radiological signs of osteomyelitis.

Bacterial culture

Oxacillin resistant *Staphylococcus aureus* (ORSA)

Operation

Complete debridement was performed and the cavity was filled with Bonalive® granules (S53P4 bioactive glass). A collagen membrane was used to receive complete soft tissue coverage of Bonalive® granules.

Pre-op

Pre-op

Immediate post-op

Clinical outcome

11 months after treatment complete osseointegration of Bonalive® granules can be observed.

Immediate post-op

11 months post-op

11 months post-op

Courtesy of Dr. Roberto De Giglio, Abbiategrasso Hospital, Milan, Italy

References

The use of bioactive glass S53P4 in the treatment of an infected Charcot foot: a case report.
Godoy-Santos AL, et al. J Wound Care. 2019 Jan 1;28(Sup1):S14-S17. doi: 10.12968/jowc.2019.28.Sup1.S14.

Bioactive glass S53P4: a new opportunity for the treatment in the diabetic foot osteomyelitis.
De Giglio R, et al. Eur J Intern Med. 2018 Aug;54:e15-e16.

The use of bioactive glass S53P4 as bone graft substitute in the treatment of chronic osteomyelitis and infected non-unions – a retrospective study of 50 patients.
Al Malat TA, et al. Z Orthop Unfall 2018;156:152-9.

Antibacterial bioactive glass, S53P4, for chronic bone infections - a multinational study.
Lindfors N, et al. Adv Exp Med Biol 2017;971:81-92.

A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis - a retrospective comparative study.
Romanò CL, et al. Bone Joint J 2014;96-B:845-50

Clinical applications of Bioactive glass S53P4 in bone infections: a systematic review.
Bigoni M, et al. Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):240-251. doi: 10.26355/eurrev_201904_17498.

BAG-S53P4 as bone graft extender and antimicrobial activity against gentamicin- and vancomycin-resistant bacteria.
Bortolin M, et al. Future Microbiology. 2018 Apr;13(5):525-33.

In vitro antibacterial activity of bioactive glass S53P4 on multiresistant pathogens causing osteomyelitis and prosthetic joint infection.
Cunha TM, et al. BMC Infectious Diseases. 2018;18:157. [Open access]

Antibiofilm agents against MDR bacterial strains: is bioactive glass BAG-S53P4 also effective?
Bortolin M, et al. J Antimicrob Chemother 2016 Jan;71(1):123-7.

Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains.
Drago L, et al. Future Microbiol. 2015;10(8):1293-9.

Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro.
Leppäranta O, et al. J Mater Sci: Mater Med. 2008;19:547-51.

Bactericidal effects of bioactive glasses on clinically important aerobic bacteria.
Munukka E, et al. J Mater Sci: Mater Med. 2008;19:27-32.